Johnson & Johnson $JNJ Shares Sold by Wealth Effects LLC

Wealth Effects LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,747 shares of the company’s stock after selling 551 shares during the period. Wealth Effects LLC’s holdings in Johnson & Johnson were worth $1,031,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of JNJ. Elios Financial Group Inc. grew its position in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after buying an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its stake in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC grew its holdings in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after acquiring an additional 68 shares in the last quarter. Sovereign Financial Group Inc. increased its position in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after purchasing an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc raised its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after purchasing an additional 69 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on JNJ. Citigroup boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Bank of America lifted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $176.62 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $425.35 billion, a PE ratio of 18.89, a P/E/G ratio of 2.25 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The business’s fifty day moving average price is $173.80 and its two-hundred day moving average price is $161.90.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.